Filing Flows

Filing Flows › NovoCure (NVCR) › Next earnings date

NovoCure (NVCR) earnings: beat the estimate

NovoCure (NVCR) reported on Oct 29, 2026 and beat the EPS estimate: −$0.09 against −$0.23 (+61.7%). Revenue was $193M for Q3 2026, +16% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+61.7% vs estimate
Beat rate80%

The last report

NovoCure reported revenue of $193M for the third quarter 2026 (+16% Y/Y), net loss $10.4M. How it makes money → · Every quarter →

NovoCure: EPS against the estimate, last 5 reportsNovoCure: EPS against the estimate, last 5 reportsEstimateReported−$0.42−$0.33Oct 25−$0.41−$0.22Feb 26−$0.51−$0.62Apr 26−$0.33−$0.13Jul 26−$0.23−$0.09Oct 26
Latest (Oct 26): Estimate −$0.23, Reported −$0.09.

NovoCure's latest quarter

NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did NovoCure beat earnings?

NovoCure (NVCR) reported on Oct 29, 2026 and beat the EPS estimate: −$0.09 against −$0.23 (+61.7%).

When does NVCR report earnings?

The next date is not set yet.

Does NovoCure usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.